Methodist Journal

IN THIS ISSUE

Diabetes and the Heart

Vol 14, Issue 4 (2019)


FEATURED GUEST EDITOR

ISSUE INTRO

The Intersection of Diabetes and Cardiovascular Disease

See More
RECOGNITIONS

Guest Editors Steven Petak and Archana Sadhu Guide Issue on Diabetes and the Heart

See More

REVIEW ARTICLES See More

Cardiac Autonomic Neuropathy in Diabetes Mellitus

Stage-Based Management of Type 2 Diabetes Mellitus with Heart Failure

Imaging to Stratify Coronary Artery Disease Risk in Asymptomatic Patients with Diabetes

Update on Management of Type 2 Diabetes for Cardiologists

New Therapeutic Strategies for Type 2 Diabetes

Prediabetes: Why Should We Care?

Central Venous Pathologies: Treatments and Economic Impact

Venous Thrombosis and Post-Thrombotic Syndrome: From Novel Biomarkers to Biology

CASE REPORTS See More

Loperamide Mimicking Brugada Pattern

Reversed Pulsus Paradoxus in Right Ventricular Failure

Mycobacterium Chimaera Mimicking Sarcoidosis

Immune Checkpoint Inhibitor Related Cardiotoxicity

MUSEUM OF HMH MULTIMODALITY IMAGING CENTER See More

A Right Ventricular Mass

CLINICAL PERSPECTIVES See More

POINTS TO REMEMBER

The Kidney as an Endocrine Organ

EXCERPTA

The Other Side of the Prescription

EXCERPTA

Telemedicine Shakes Up the ICU Experience

POINTS TO REMEMBER

Venous Thrombosis in Nephrotic Syndrome

EDITORIALS

Letter to the Editor in response to “Role of Subcutaneous Leadless Implantable Cardioverter Defibrillator in Young Patients

Vol 14, Issue 4 (2019)

Article Abstract

New Therapeutic Strategies for Type 2 Diabetes


Article Citation:

Yehya A, Sadhu A. New Therapeutic Strategies for Type 2 Diabetes. Methodist DeBakey Cardiovasc J. 2018;14(4):281-88.

doi:

Abstract

Pharmacological options for treatment of type 2 diabetes (T2D) have advanced rapidly during the last 10 years, allowing clinicians to target different pathophysiological defects in this disease. There are currently 12 different classes of drugs available to treat T2D. The most exciting development is the demonstration of cardiovascular (CV) benefits from two of these new classes, the glucagon-like peptide-1 receptor agonists (GLP-1 RA) and selective sodium glucose transporter 2 (SGLT2) inhibitors. These drugs have challenged conventional algorithms in the management of T2D by exceeding expectations in cardiovascular outcome trials and demonstrating an unexpected reduction in CV events. This review focuses on the physiologic actions and the CV outcomes associated with dipeptidyl peptidase-4 (DPP-4) inhibitor, GLP-1 RA, and SGLT2 inhibitor use. Understanding their potential may revolutionize our approach to the management of T2D.

Keywords
incretins , GLP-1 RA , DPP-4 , SGLT2 , cardiovascular disease , heart failure , myocardial infarction , type 2 diabetes